NASDAQ · CVKD
Healthcare · Biotechnology
$1.71
Down-$0.04 (-2.29%)
Updated Aug 19, 2026, 8:19 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
CVKD closed at $1.71 after 21 trading sessions, down 21.20% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $1.76 | $1.82 | $1.64 | $1.71 | 59.49K |
| Aug 17, 2026 | $1.88 | $1.88 | $1.71 | $1.76 | 37.2K |
| Aug 14, 2026 | $1.88 | $1.9139 | $1.79 | $1.87 | 27.91K |
| Aug 13, 2026 | $1.85 | $1.9686 | $1.76 | $1.86 | 35.86K |
| Aug 12, 2026 | $1.9448 | $1.98 | $1.77 | $1.84 | 63.74K |
| Aug 11, 2026 | $1.975 | $2.12 | $1.92 | $1.94 | 46.33K |
| Aug 10, 2026 | $1.96 | $2.0126 | $1.91 | $1.94 | 19.98K |
| Aug 7, 2026 | $1.90 | $2.05 | $1.87 | $1.95 | 30.08K |
| Aug 6, 2026 | $1.98 | $1.9908 | $1.87 | $1.87 | 25.72K |
| Aug 5, 2026 | $2.07 | $2.10 | $1.90 | $1.96 | 33.04K |
| Aug 4, 2026 | $1.96 | $2.17 | $1.96 | $2.03 | 40.67K |
| Aug 3, 2026 | $1.97 | $2.16 | $1.90 | $1.96 | 40.92K |
| Jul 31, 2026 | $2.08 | $2.11 | $1.97 | $2.01 | 14.94K |
| Jul 30, 2026 | $2.01 | $2.09 | $1.9614 | $2.09 | 17.77K |
| Jul 29, 2026 | $1.99 | $2.05 | $1.96 | $1.97 | 13.77K |
| Jul 28, 2026 | $2.06 | $2.095 | $1.98 | $2.01 | 32.73K |
| Jul 27, 2026 | $2.14 | $2.14 | $1.95 | $2.06 | 71.12K |
| Jul 24, 2026 | $2.05 | $2.16 | $1.92 | $2.04 | 80.26K |
| Jul 23, 2026 | $2.05 | $2.125 | $1.86 | $2.03 | 59.7K |
| Jul 22, 2026 | $2.17 | $2.2417 | $2.05 | $2.10 | 39.37K |
| Jul 21, 2026 | $2.14 | $2.3852 | $2.10 | $2.17 | 168.42K |
The latest Smart Investors Daily articles mentioning CVKD.
CVKD research
Company profile and research snapshot.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 7, 2026 | HC Wainwright & Co. | Buy | — |
| May 16, 2025 | HC Wainwright & Co. | Buy | — |
| Nov 11, 2024 | HC Wainwright & Co. | Buy | — |
| Jun 6, 2024 | HC Wainwright & Co. | Buy | — |
| May 9, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 3, 2026
Urgent Need for Novel Targets - Recent clinical failure of a competing mechanism highlights urgent need for novel upstream targets, such as 12-LOX, that are being studied to address the root causes of cardio-renal
Benzinga · Jul 21, 2026
Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditionsCompany is exploring development, licensing, and commercialization
Benzinga · Jul 13, 2026
Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis, CAD-1005 took center stage before the global thrombosis community at the largest ISTH meeting in more than a
Benzinga · Jun 29, 2026
-SEC Filing
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CVKD.
